Featured
Genitourinary syndrome of menopause (GSM) got its first formal guideline in 2025, and vaginal estrogen data link it to fewer infections and hospitalizations. Here is the symptom most women are never told about.
In February 2026 the FDA removed the boxed cardiovascular, breast-cancer, and dementia warnings from six menopausal hormone therapy products. Here is what changed, what did not, and who should still be careful.
The 2026 ACC/AHA dyslipidemia guideline says every adult should be tested once for Lp(a), adds ApoB and 30-year risk, and brings back specific LDL targets. Here is what the changes mean for you.
The 2026 MAHA agenda pushes supplement oversight and GRAS reform, yet peptides like BPC-157 are sold as 'research only' outside drug rules. Here is the regulatory contradiction and the risk to buyers.
The 2026 Medicare sleep-apnea changes added prior authorization in six states, a 12-month sleep-study validity window, and a strict 4-hour compliance rule. Here is what beneficiaries must do to keep coverage.
The 2026 CDC RSV guidance says adults 75+ and at-risk adults 50–74 should get one dose, and it is not an annual shot. Here is the timing and the group that qualifies this season.
The FDA has now cleared more than 1,000 AI-enabled medical devices, with radiology leading the way. Here is what clearance actually means, where the evidence is solid, and what to watch for.
The FDA approved bemotrizinol in June 2026, the first new sunscreen active ingredient in more than two decades. Here is what it does, how it differs from current filters, and when it will reach shelves.
The 2026 ACC/AHA dyslipidemia guideline replaces the 2018 recommendations with earlier screening, new PREVENT risk equations, universal Lp(a) testing, and lower LDL-C targets for many patients.
The AHA and ACC issued the first clinical guideline for cardiovascular-kidney-metabolic syndrome in June 2026. Here is what the four-stage system means for your care.
Congress and the FTC took aim at pharmacy benefit managers in 2026. Here is what changed, when it takes effect, and how it could lower your prescription costs.
The 2026 Dysautonomia International conference launched a new ME/CFS biobank, and recent studies identified potential blood-based biomarkers for post-exertional malaise. Here is what is ready now and what remains experimental.
:max_bytes(150000):strip_icc()/VWM-ADHDinWomenSignsandSymptoms_final-efbb964a72474f06a5f9b1eae2eec62c.png)
Perimenopause and ADHD share strikingly similar symptoms. A 2025 population study found women with ADHD report nearly double the rate of severe perimenopausal symptoms.
The EPA issued new interim guidance on PFAS destruction and disposal in April 2026, and NRDC warned that PFAS microplastics are a global contaminant found in human blood, placenta, lung tissue, and semen. Here is what to do now.
A June 2026 JACC subgroup analysis of the FLOW trial confirmed that semaglutide reduces major kidney events and death consistently across cardiovascular subgroups in type 2 diabetes and chronic kidney disease.
New studies show semaglutide can accelerate muscle loss in older adults with type 2 diabetes, especially at higher doses. Here is what clinicians recommend for protection.
Obstructive sleep apnea triggers hypoxia-driven kidney injury through inflammation and blood pressure spikes. New data confirm that consistent CPAP use slows kidney function decline in chronic kidney disease patients.
A European phase 2 trial found the existing epilepsy drug sulthiame reduced sleep apnea breathing interruptions by up to 47%. It is not a replacement for CPAP yet, but it is the strongest signal yet that a pill-based approach may work.
